Abstract
Introduction Atrial septal aneurysms increase the risk of stroke recurrence in cryptogenic stroke patients with a patent foramen ovale. Factors related to stroke recurrence according to the patent foramen ovale risk stratification have not been fully evaluated.
Methods Data from a multicenter observational registry of ischemic stroke patients undergoing transesophageal echocardiography, with a comprehensive database including clinical characteristics and long-term prognosis, were used for this study. Patients were classified into three groups: high-risk patent foramen ovale group, large shunt patent foramen ovale (≥20 microbubbles) or patent foramen ovale with atrial septal aneurysm; right-to-left shunt group, right-to-left shunt including patent foramen ovale with <20 microbubbles or without atrial septal aneurysm; and negative right-to-left shunt group. Among stroke subtype, factors related to stroke recurrence were investigated according to the risk stratification of patent foramen ovale in cryptogenic stroke.
Results In total, 586 patients (185 females; 65.5 ± 13.2 years) were analyzed. In cryptogenic stroke (329 patients) with median follow-up of 4.2 (interquartile range, 1.0– 6.1) years, 55 patients had stroke recurrence. The negative right-to-left shunt, right-to-left shunt, and high-risk patent foramen ovale groups included 179, 90, and 60 patients, in which stroke recurrence occurred in 5.3%, 2.5%, and 4.6% per person-year, respectively. In patients with high-risk patent foramen ovale, the NIH stroke scale score (hazard ratio 1.257, 95% CI 1.034-1.530, P=0.022) and periventricular hyperintensity (hazard ratio 3.369, 95% CI 1.103-10.294, P=0.035) were predictive markers for stroke recurrence on multivariate Cox Hazards analysis, but no factors were related to stroke recurrence in the right-to-left shunt and negative right-to-left shunt groups.
Conclusion High-risk patent foramen ovale is an important embolic source in cryptogenic stroke. Periventricular hyperintensity was shown to predict recurrent stroke in patients with a high-risk patent foramen ovale. In such cases, percutaneous patent foramen ovale closure might be effective at <60 years of age.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded, in part, by the BMS/Pfizer Japan Thrombosis Investigator Initiated Research Program (JRISTA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Independent Ethics Committee of Juntendo University Hospital
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability statement
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
